XML 22 R5.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]    
Research and development revenue $ 29,581 $ 18,056
Cost of revenue (16,307) (10,176)
Gross profit 13,274 7,880
Operating costs and expenses:    
General and administrative 19,856 20,864
Total operating costs and expenses 19,856 20,864
Operating loss (6,582) (12,984)
Other income (expense):    
Net interest income 14 172
Borrowing related costs (2,965)
Change in fair value of warrant liabilities (4,633) 335
Change in fair value of notes payable (220)
Foreign exchange transaction loss, net (43) (24)
Other expenses, including transaction costs (615) (8,342)
Total other expense, net (8,462) (7,859)
Loss before income taxes (15,044) (20,843)
Income tax provision (271) (11)
Net loss $ (15,315) $ (20,854)
Net loss per share of common stock    
Basic (in Dollars per share) $ (0.85) $ (1.48)
Diluted (in Dollars per share) $ (0.85) $ (1.48)
Weighted-average common shares outstanding    
Basic (in Shares) 17,934,218 14,087,586
Diluted (in Shares) 17,934,218 14,087,586
Other comprehensive income:    
Foreign currency translation adjustments $ (9) $ 12
Total comprehensive loss $ (15,324) $ (20,842)